Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis

Publish date:: December 16, 2020

Key clinical point: Patients with suspected nonradiographic axial spondyloarthritis but without positive MRI signs of sacroiliitis and/or elevated C-reactive protein levels show no response to etanercept.

Major finding: Researchers observed similar clinical improvements at 16 weeks in the etanercept and placebo arms of the study.

Study details: A randomized, double-blind, placebo-controlled trial in 80 patients with suspected nonradiographic axial spondyloarthritis.

Disclosures: The study was supported by an unrestricted financial grant from Pfizer and ReumaNederland. No conflicts of interest were declared.

Citation:

Rusman T et al. Arthritis Rheumatol. 2020 Dec 5. doi: 10.1002/art.41607.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Rheumatology

Osteoporosis prevalence in PsA similar to general population,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,